Results 171 to 180 of about 1,837,020 (236)
Some of the next articles are maybe not open access.
Journal of Immunology, 1994
Vaccine-induced, virus-specific CTLs may rapidly eliminate the host cells that first become infected after virus exposure, thereby preventing disseminated infection.
Emil P. Miskovsky +9 more
semanticscholar +1 more source
Vaccine-induced, virus-specific CTLs may rapidly eliminate the host cells that first become infected after virus exposure, thereby preventing disseminated infection.
Emil P. Miskovsky +9 more
semanticscholar +1 more source
Science, 2008
A quarter century of scientific discovery has been applied to developing an AIDS vaccine, yet this goal remains elusive. Specific characteristics of the virus, including the extreme genetic variability in circulating viral isolates worldwide, biological properties of HIV that impede immune attack, and a high mutation rate that allows for rapid escape ...
Bruce D, Walker, Dennis R, Burton
openaire +2 more sources
A quarter century of scientific discovery has been applied to developing an AIDS vaccine, yet this goal remains elusive. Specific characteristics of the virus, including the extreme genetic variability in circulating viral isolates worldwide, biological properties of HIV that impede immune attack, and a high mutation rate that allows for rapid escape ...
Bruce D, Walker, Dennis R, Burton
openaire +2 more sources
Vaccine, 1999
In spite of extensive prevention programs, the HIV epidemics is still spreading worldwide, in particularly in developing countries where clade C viruses predominate. WHO estimates that there are 16, 000 new cases of HIV infection daily and that 100 M individuals will be infected by the end of the next decade.
openaire +2 more sources
In spite of extensive prevention programs, the HIV epidemics is still spreading worldwide, in particularly in developing countries where clade C viruses predominate. WHO estimates that there are 16, 000 new cases of HIV infection daily and that 100 M individuals will be infected by the end of the next decade.
openaire +2 more sources
International Archives of Allergy and Immunology, 2009
The identification of a virus, HIV-1, as the etiological agent of AIDS has opened the door to the development of a vaccine against this disease, for both prophylactic and therapeutic purposes. A number of different vaccine strategies have been developed in pursuit of this aim.
Noel Barrett, Friedrich Dorner
openaire +1 more source
The identification of a virus, HIV-1, as the etiological agent of AIDS has opened the door to the development of a vaccine against this disease, for both prophylactic and therapeutic purposes. A number of different vaccine strategies have been developed in pursuit of this aim.
Noel Barrett, Friedrich Dorner
openaire +1 more source
Journal of Immunology, 1995
We examined the humoral immune response in both HIV-1 infected and uninfected volunteers immunized with candidate HIV-1 recombinant envelope subunit vaccines (Genentech gp120IIIB, MicroGeneSys gp160IIIB, or ImmunoAG gp160IIIB). Immunization of both HIV-1
T. VanCott +4 more
semanticscholar +1 more source
We examined the humoral immune response in both HIV-1 infected and uninfected volunteers immunized with candidate HIV-1 recombinant envelope subunit vaccines (Genentech gp120IIIB, MicroGeneSys gp160IIIB, or ImmunoAG gp160IIIB). Immunization of both HIV-1
T. VanCott +4 more
semanticscholar +1 more source
The Prospects for AIDS Vaccines
Hospital Practice, 1991Several vaccine strategies against HIV are under study in phase 1 clinical trials. Many involve recombinant subunit preparations, and the question is which of these components of the virus may be immunogenic. Immune effectors and mediators that protect against HIV are also undefined. Vaccines may ultimately be used to treat as well as prevent AIDS.
openaire +2 more sources
Current Opinion in HIV and AIDS, 2006
The year 2005 saw the licensure of two DNA vaccines for veterinary use (horses and salmon), thus demonstrating that limitations of potency and delivery have been overcome for certain real-life applications. The purpose of this review is to evaluate the advances specific for application of DNA vaccines to HIV vaccines for humans.The potency of DNA ...
Jeffrey B, Ulmer +2 more
openaire +2 more sources
The year 2005 saw the licensure of two DNA vaccines for veterinary use (horses and salmon), thus demonstrating that limitations of potency and delivery have been overcome for certain real-life applications. The purpose of this review is to evaluate the advances specific for application of DNA vaccines to HIV vaccines for humans.The potency of DNA ...
Jeffrey B, Ulmer +2 more
openaire +2 more sources
Will There Be an AIDS Vaccine?
Science News, 1987E ver since 18th-century physician Edward Jenner used a dairymaid's cowpox lesions to successfully inoculate a boy against smallpox, vaccines have been indispensable in the fight against infectious diseases. It's no wonder, then, that people might turn toward a vaccine in hopes of stemming the modern-day plague of AIDS. Indeed, as a National Academy of
openaire +1 more source
JAMA, 1994
Worldwide, the human immunodeficiency virus type 1 (HIV-1) has already infected 10 million to 15 million people. With an estimated 5000 to 10 000 new infections occurring each day, 30 million to 40 million people will be infected by the year 2000. 1 In developing countries, where more than 80% of new infections are occurring, the virus is predominantly
openaire +1 more source
Worldwide, the human immunodeficiency virus type 1 (HIV-1) has already infected 10 million to 15 million people. With an estimated 5000 to 10 000 new infections occurring each day, 30 million to 40 million people will be infected by the year 2000. 1 In developing countries, where more than 80% of new infections are occurring, the virus is predominantly
openaire +1 more source